All In MedTech

Device Trial Radar · NCT07939360

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction.

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Essilor InternationalNot on our public-company list
Sponsor type
Industry
First posted
Nov 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6) months, and subject participation will take approximately four (4) weeks, including three (4) visits; pretreatment visit, Treatment Day, two (2) week follow-up and four (4) week follow-up visits. The investigational therapy in this study is the use of low-level light therapy (LLLT) for the treatment of evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands. Low-Level Light Therapy (LLLT) is a treatment that uses gentle light to help patient cells work better. The light is applied to the skin using special devices. This light can help repair cells that are damaged and improve the function of healthy cells. It may also warm the natural oils in patient eyelids and could reduce tiny mites that sometimes live near the eyelashes. These effects may support overall eye health and comfort. Participants will be randomized to receive treatment using the Equinox System (red mask) or iLux 2020 System ("iLux system"). There is a 50% chance participant will receive treatment with the Equinox System (red mask) and 50% chance participant will receive treatment with the iLux 2020 System. For treatment, participant will be placed in either the prone or supine position. Participant will then wear the red mask for 17 minutes. Special protective eyewear or eye protection is not indicated for this treatment; participant will be instructed to keep eyes closed to ensure full application of the treatment to the upper and lower lids and the periorbital area. Immediately after the treatment is finished, the mask will be removed and the meibomian glands will be manually expressed by a trained and qualified clinician.

Conditions

  • Dry Eye
  • Dry Eyes Chronic

Interventions

  • low-level light therapyDevice

    Equinox mask used to deliver low-level light therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Meibomian Gland Score (MGS)Time frame: 4 weeks
  2. Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Tear Break-Up Time (TBUT)Time frame: 4 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • MRB Eye Consultants, LLC

    Scottsdale, Arizona

  • East West Eye Institute

    Torrance, California

  • Louisville Eye Center PLLC

    Louisville, Kentucky

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.